Key facts
- This page summarizes Daniel E. Geffken's Form 4 filing for Eloxx Pharmaceuticals, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 01 Dec 2021, 10:06.
Daniel E. Geffken - 29 Nov 2021 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc.
- Reporting relationship
- INTERIM CFO
- Issuer ticker
- ELOX on Nasdaq, ELOXD on OTC
- Reported as of
- 29 Nov 2021
- Net transaction value
- +$36,000
- SEC form
- 4
- Accepted by SEC
- 01 Dec 2021, 10:06:56 UTC
- Prior SEC filing
- 12 Oct 2021
- Next SEC filing
- 09 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Daniel E. Geffken
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel E. Geffken filed Form 4 for Eloxx Pharmaceuticals, Inc. on 01 Dec 2021.
Change
- Previous filing in this sequence was filed on 12 Oct 2021.
- Current net transaction value: +$36,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ELOX
transaction
Common Stock
Purchase
- Transaction value
- $36,000
- Shares
- +50,000
- Change %
- Price
- $0.7200
- Shares after
- 50,000
- Date
- 29 Nov 2021
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Price represents the average purchase price per share.